저자: 미상 · 외국인
요약 보기
캐시 우드(ARK)가 시장 급변기에 자율주행 로보택시·유전자편집·크립토 인프라 테마로 포지션을 재편 중이라 주장. 대표 종목으로 Pony.ai(2026 로보택시 매출 목표 2025년의 3.5배 이상, 1분기 매출 34.3M달러 145%↑, 순손실 53.5M달러), Coinbase(1분기 매출 14.1억달러, 조정 EBITDA 3.03억달러, GAAP 순손실 3.94억달러), Beam Therapeutics(1분기 협업·라이선스 매출 31.7M달러, 순손실 94.3M달러) 제시. 단기 변동성은 매수 기회로 보며 적극 편입을 권유하나 투자자문이 아니라고 고지.
다듬은 글
The markets are cracking. Legacy tech is cracking under pressure. Inflation whispers are turning into roars, but while Wall Street panics, Cathie Wood is doing what she does best, betting boldly on the future. She's trimming, selling, and reallocating aggressively from yesterday's winners like Roku, AMD, and others to load up massively on the next trillion-dollar disruptors.
This isn't just another portfolio tweak. This is Cathie declaring the fleet of self-driving robotaxis transforming urban mobility, breakthrough gene editing cures rewriting human health, and crypto infrastructure powering the next financial revolution all accelerating faster than anyone imagined. If you're still holding onto the old world, you could be left behind.
But those who follow her conviction, they could be positioned for life-changing gains in 2026 and beyond. Today, we're diving deep into the three stocks she's buying heavily right now with fresh updates, explosive developments, and the latest financials that scream opportunity. Stay tuned because by the end of this video, you'll understand exactly why urgency meets unstoppable optimism in Cathie's playbook.
Pony.ai Pony, the robotaxi and autonomous driving commercialization powerhouse. Pony.ai Pony stands as a global leader in autonomous driving technology, pioneering large-scale mass production and commercialization through its advanced Pony World platform and virtual driver system. They are rapidly deploying robotaxis and robotrucks, turning cutting-edge AI autonomy into profitable, real-world mobility solutions across multiple cities and international markets.
Pony.ai is in full acceleration mode following strong Q1 results. The company raised its full-year 2026 robotaxi revenue target to more than 3.5 times 2025 levels up from previous 3x guidance and increased its year-end robotaxi fleet size goal to over 3,500 vehicles across more than 20 cities. By May 2026, registered robotaxi users in China had already tripled year-over-year with operations achieving city-level unit profitability.
Fair charging revenues are surging as they expand into prime downtown areas and peak hour coverage. Additional tailwinds include partnerships such as with Uber, Gen 7 robotaxi deployments, intelligence solutions, ADC shipments growth, RoboTruck long-haul expansion, and international traction. This marks a clear commercialization inflection positioning Pony.ai as a frontrunner in the autonomous mobility revolution that Kathy Wood has long highlighted.
Total revenue exploded 145% year-over-year to $34.3 million dollars significantly beating expectations. Robotaxi revenue skyrocketed 395.4% to $8.6 million dollars with fair charging revenue within that up an astonishing 456.5%. Intelligence solutions revenue grew 246% to $15.5 million dollars and RoboTruck revenue rose 31% to $10.2 million dollars.
Gross profit reached approximately $5.6 million dollars gross margin 16.2%. While net loss widened to $53.5 million dollars or minus 12 cents per share due to heavy R&D and scaling investments, operating leverage is improving and cash reserves stand strong at $1.4 billion dollars. Management emphasized the strong start sets the stage for sustained hypergrowth throughout 2026.
Coinbase coin the leading crypto infrastructure and everything exchange builder. Coinbase coin is the premier US-based cryptocurrency platform offering secure trading, custody, stablecoin derivatives, and institutional services while aggressively expanding into a full everything exchange with tokenized assets, prediction markets, and broader financial integrations.
It serves as a trusted on-ramp and infrastructure layer for retail and institutional crypto adoption. Despite softer crypto market conditions in Q1, Coinbase demonstrated resilience by achieving an all-time high crypto trading volume market share of 8.6% driven by product innovation and derivatives growth, retail derivatives annualized revenue exceeding $200 million.
The company executed cost optimizations, including workforce adjustments focused on AI efficiency and lowered full-year expense guidance. Progress continues on regulatory clarity initiatives, stablecoin expansions, and new offerings like tokenized equities. ARK Invest under Cathie would maintain significant exposure to coin as a core long-term holding in the crypto and blockchain theme.
As Bitcoin cycles evolve and institutional adoption deepens, Coinbase platform moat, diversification, and everything exchange strategy provide durability and upside. Q1 2026 total revenue reached $1.41 billion with with adjusted EBITDA at a solid plus $303 million marking the 13th consecutive positive quarter.
The company reported a GAAP net loss of $394 million or minus $1.49 per share, primarily impacted by market-driven volume declines and unrealized investment losses. But demonstrated strong cost discipline. Subscription and services revenue showed resilience and management highlighted market share gains as foundational for recovery and growth as conditions improve.
Beam Therapeutics Beam, the precision-based editing genetic medicine pioneer. Beam Therapeutics Beam is revolutionizing genetic medicine with its proprietary base editing technology, developing one-time potentially curative therapies for serious diseases including sickle cell disease, alpha-1 antitrypsin deficiency ATD, phenylketonuria PKU, and glycogen storage disease.
Their precise editing approach minimizes risks compared to traditional CRISPR, offering new hope for patients with limited treatment options. Q1 2026 financials, collaboration and license revenue surged to $31.74 million, substantially beating estimates of $11 million. Net loss was $94.3 million or minus $0.91 per share, which outperformed consensus expectations of around minus $1.03.
R&D expenses remain focused on advancing the pipeline, while the strong balance sheet provides ample flexibility for pivotal trials and launches. This financial discipline combined with clinical momentum positions Beam for potential value inflection points ahead. Cathie Wood's visionary framework in Big Ideas 2026 points directly to autonomy, genetic medicines, and crypto as transformative forces.
Pony.ai, Beam Therapeutics, and Coinbase deliver pure-play access to these themes. With impressive commercial scaling, clinical advancements, strategic execution, robust pipelines, and market leadership. Short-term volatility for market cycles or investment phases is normal. Treat those dips as opportunities to add heavily.
The long-term optimism is grounded in accelerating adoption, technological breakthroughs, and enormous total addressable markets that could drive substantial compounding. Sell the distractions and noise. Heavily position in the future today. Always conduct your own thorough due diligence. Consider your personal risk tolerance, time horizon, and consult financial professionals.
This is not financial advice. Which of these three are you loading up on first? Drop it in the comments. Smash like if you're aligning with Cathy's disruptive vision. Subscribe for more high conviction alpha and hit the notification bell. Let's ride the innovation supercycle together. I'll see you in the next video. Stay ahead of the curve.
댓글 0